BIBLIOGRAFIA:

1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
2. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 06 de 2018;9(2).
3. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 22 de mayo de 2020;
4. Ritonavir Dosificación, Efectos secundarios [Internet]. infoSIDA. [citado 11 de junio de 2020]. Disponible en: https://infosida.nih.gov/drugs/244/ritonavir/0/patient
5. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 1 de marzo de 2004;59(3):252-6.
6. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.
7. Lineamientos tecnicos para la atención clinica de personas con COVID-19. Ministerio de Salud (MINSAL) [Internet]. Disponible en: http://asp.salud.gob.sv/regulacion/pdf/lineamientos/lineamientostecnicosparalaatencionclinicadepersonasconCOVID19TE.pdf
8. Lopinavir/Ritonavir and Other HIV Protease Inhibitors | Coronavirus Disease COVID-19 [Internet]. COVID-19 Treatment Guidelines. [citado 12 de junio de 2020]. Disponible en: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/lopinavir-ritonavir-and-other-hiv-protease-inhibitors/
9. Hoja informativa para proveedores de atención médica autorización de uso urgente (EUA) de fosfato de cloroquina proporcionado por la reserva estratégica nacional para el tratamiento del covid-19 en ciertos pacientes hospitalizados [Internet]. [Citado 12 de junio de 2020]. Disponible en: https://www.fda.gov/media/137437/download
10. Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. abril de 2004;136(1):95-103.
11. Qin Y-Y, Zhou Y-H, Lu Y-Q, Sun F, Yang S, Harypursat V, et al. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial. Chinese Medical Journal. 5 de mayo de 2020;133(9):1080–1086.
12. Bosseboeuf E, Aubry M, Nhan T, de Pina JJ, Rolain JM, Raoult D, et al. Azithromycin Inhibits the Replication of Zika Virus. J Antivir Antiretrovir [Internet]. 2018 [citado 14 de junio de 2020];10(1). Disponible en: https://www.omicsonline.org/open-access/azithromycin-inhibits-the-replication-of-zika-virus-1948-5964-1000173-99806.html
13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. marzo de 2020;395(10229):1054-62. 14. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 11 de mayo de 2020; 15. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 01 de 2020;130(6):2757-65.
16.lineamientostecnicosparausodeplasmaconvalecienteenpacientesconCOVID19-Acuerdo821_v2.pdf [Internet]. [citado 14 de junio de 2020]. Disponible en:http://asp.salud.gob.sv/regulacion/pdf/lineamientos/lineamientostecnicosparausodeplasmaconvalecienteenpacientesconCOVID19-Acuerdo821_v2.pdf
17. Dumont LJ, Cancelas JA, Maes LA, Rugg N, Whitley P, Herschel L, et al. The bioequivalence of frozen plasma prepared from whole blood held overnight at room temperature compared to fresh-frozen plasma prepared within eight hours of collection. Transfusion. marzo de 2015;55(3):476-84.
18. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2 de abril de 2020;12(4).